Nephron [creativecommons license] via Wikimedia Commons
Ovarian clear-cell carcinoma (OCCC) is an aggressive form of cancer. Although its incidence is not high, accounting for 5–20% of all epithelial ovarian cancers (EOCs), it has a poorer prognosis, higher recurrence and lower survival than other EOC types, particularly when diagnosed at advanced stages. A better understanding of OCCC development and progression could lead to improved treatments and outcomes for those affected, and a new tool for studying OCCC holds promise for delivering this necessary insight. Scientists at University of North Carolina (Chapel Hill) recently announced the creation of a genetically engineered mouse model of OCCC that recapitulates the disease in humans. The model could be used to test potential therapies and to identify disease markers for diagnostic screening.
Lab Anim. (NY) 44, 75 (2015).
view full text (login required)